Now Live The BioInsights Podcast Modernizing cell therapy manufacturing to reduce vein-to-vein times

Listen now

GPB Scientific Increases Second Tranche of Venture-backed Growth Financing from $10 to $ 18 million to Support Commercialization of Curate® Cell Processing System

GPB Scientific, Inc., a developer of transformative cell processing technology for next generation cell and gene therapies, today announced raising an additional $18 million in capital as part of a previously announced financing, including commitments from existing investors Vensana Capital and Amgen Ventures, and from a new undisclosed healthcare investor. This financing will support expanded placements of GPB’s Curate® Cell Processing System into partner facilities to enable optimized development and manufacturing in CAR-T and TCR programs, as well as development of the platform’s utility in additional types of cell and gene therapy applications…

Read the full story.